(News Bulletin 247) – Merck provided an update last night on a phase II trial evaluating MK-7684A, a co-formulation of vibostolimab and pembrolizumab (Keytruda), with or without docetaxel, for the treatment of patients patients with non-small cell lung cancer (NSCLC), with progressive disease after treatment with immunotherapy and platinum-based doublet chemotherapy.

Results from the open arm of this study show that the coformulation did not achieve the primary endpoint of progression-free survival (PFS) and was numerically less effective than docetaxel.

Merck advises study investigators that patients in this arm of the study should be transitioned to standard therapy unless otherwise directed by the physician.

‘Based on the responses we have seen to date in the Phase 1/2 signal research program, we are continuing our comprehensive research program evaluating MK-7684A in a wide range of cancers, including lung, other solid tumors and blood cancers,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer at Merck Research Laboratories.

Copyright (c) 2023 News Bulletin 247. All rights reserved.